anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a pharmaceutical composition for preventing or treating thrombosis comprising a Sphagnum palustre extract and a health functional food comprising the Sphagnum palustre extract and, more particularly, to a pharmaceutical composition for preventing or treating thrombosis comprising a hot water extract of Sphagnum palustre, organic solvent fractions, and water-soluble water residues after organic solvent fractionation as active components, and a health functional food comprising the same. Water residues obtained after sequential organic solvent fractionation of a Sphagnum palustre extract of the present invention, particularly a hot water extract of Sphagnum palustre, have effects that are capable of efficiently suppressing the generation of thrombosis by exhibiting strong antithrombotic activities, and have excellent effects that the water residues can be used for preventing and treating thrombosis such as ischemic stroke and hemorrhagic stroke by improving blood circulation. Further, a Sphagnum palustre extract of the present invention can be safely used without hemolytic activities for human red blood cells, has excellent thermal stability, and does not exhibit losses of activities even at an acidic condition of pH 2 and in human plasma. Therefore, a Sphagnum palustre extract of the present invention is processed into various forms such as an extract, an emulsion, a powder, a pill, a tablet and others such that the Sphagnum palustre extract can be used very usefully in pharmaceutical and food industries. A pharmaceutical composition for preventing or treating thrombotic diseases comprises a Sphagnum palustre extract as an active component, wherein the Sphagnum palustre extract is extracted from water, ethanol, or a mixed solution thereof, wherein the Sphagnum palustre extract is one or more selected from the group consisting of an ethyl acetate fraction, a butanol fraction, and water residues obtained by sequentially fractionating the extract with hexane, ethyl acetate, and butanol after obtaining an extract from water, ethanol, or a mixed solution thereof, wherein the Sphagnum palustre extract is water residues remaining after fractionating a hot water extract of Sphagnum palustre with hexane, ethyl acetate, and butanol, and wherein the Sphagnum palustre extract has fibrin clotting inhibition activity. A health functional food for preventing or treating thrombotic diseases comprises a Sphagnum palustre extract as an active component.
Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine MTD. AZD5153 will be taken as oral capsules BID in combination with 300 mg olaparib BID for 21 days.
Currently, the most frequently used surgical treatment for symptomatic, benign, premalignant cystic and neuroendocrine neoplasms of the pancreatic head is the Whipple procedure or pylorus-preserving pancreatoduodenectomy (PD). However, when performed for treatment of benign tumors, PD is a multiorgan resection involving loss of pancreatic and extrapancreatic tissue and functions. PD for benign neoplasm is associated with the risk of considerable early postoperative complications and an in-hospital mortality of up to 5%. Following the Whipple procedure a new onset of diabetes mellitus is observed in 14-20% and new exocrine insufficiency in 25-45%, leading to metabolic dysfunction and impairment of quality of life persisting after resection of benign tumors. Symptomatic neoplasms are indication for surgery. Patients with asymptomatic pancreatic tumors are treated according to the criteria of surveillance protocols. The goal of surgical treatment for asymptomatic patients is, according to the guideline criteria, interruption of the surveillance program before the development of an advanced stage cancer associated with the neoplasm. Tumor enucleation and duodenum-preserving pancreatic head resection, either total or partial, are parenchyma-sparing resections for benign neoplasms of the pancreatic head. The first choice for small tumors is enucleation; however, enucleation is associated with an increased risk of pancreatic fistula B + C following pancreatic main duct injury. Duodenum-preserving total or partial pancreatic head resection has the advantage of low postoperative surgery-related complications, a mortality of < 0.5% and maintenance of the endocrine and exocrine pancreatic functions. Parenchyma-sparing pancreatic head resections should replace classical Whipple procedures for neoplasms of the pancreatic head.
Osteoarthritis (OA) is the most common form of arthritis worldwide. OA causes major disability and pain and places a huge financial burden on healthcare worldwide. In recent work, the gene expression profile of bone marrow lesions (BML) in osteoarthritis has been evaluated. BML in OA have a novel gene expression profile which includes genes involved in inflammation, neurogenesis and matrix turnover. The plan is to investigate the functional significance of the genes found at the protein biomarker level in studies of joint tissue, blood and urine from participants with knee OA and compare these changes with participants who have other forms of arthritis, including rheumatoid arthritis and spondyloarthritis.

A study amendment was added in April 2020 due to Covid-19. We are studying up to 150 additional participants with or without inflammatory conditions who are being treated with immunomodulatory drugs compared with participants who are not on immunomodulators. We will be evaluating the course of Covid-19 infection in people without autoimmune inflammatory conditions, compared with people who have autoimmune inflammatory diseases who are on immunomodulators.
The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
PURPOSE:The titled cosmetic, obtained by incorporating an extract of a stem, leaf or root of Angelica Keiskei Koidz. with hot water or ethanol in a cosmetic base, and having improved whitening and antisuntan effect and high safety. CONSTITUTION:A safe whitening cosmetic obtained by incorporating an extract of a stem, leaf or root of Angelica Keiskei Koidz. with hot water or ethanol in a cosmetic base. The component extracted from an umbelliferous plant, particularly the stem or root of Angelica Keiskei Koidaz. is found to have improved inhibitory action on melanization. The angelica Keiskei Koidz. is the umbelliferous plant growing naturally on the Pacific coast, and the leaf or stem, etc. thereof is extracted as follows; In the case of extraction with hot water, the dried Angelica Keiskei Koidz. ins finely cut. dipped in purified water, boiled, allowed to stand at ordinary temperature and filtered to collect a leachate. The amount of the extract from the Angelica Keiskei Koidz. to be incorporated in the cosmetic is preferably 0.01-1%. In the case of toilet water, a humectant, etc. are dissolved in purified water, etc. and a perfume, etc. are dissolved in an alcohol. The above-mentioned extract is added to either one thereof and mixed to prepare the titled cosmetic.
The invention relates to a maduramicin ammonium nicarbazin premix and a preparation method thereof. The premix is prepared by dissolving maduramicin ammonium in a corresponding solvent, and then spraying the solution onto nicarbazin and an auxiliary material that are uniformly mixed in a fluidized bed. The solvent can be one or more of a 40%-95% ethanol solution, benzyl alcohol, ethyl acetate and the like. The auxiliary material can be selected from the following: corn starch, plaster stone, corncob powder, anhydrous glucose, talcum powder, and calcium carbonate, etc. The combined use of maduramicin ammonium and nicarbazin can achieve a synergistic anticoccidial effect, not only can inhibit coccidia growth, but also can kill coccidian. The premix is mainly used for prevention and control of chicken coccidiosis. The preparation method of the premix is simple and feasible, has a very good uniform mixing effect, and can effectively avoid various degrees of chicken poisoning phenomena caused by uneven mixing.
Calorie restriction (CR) is known to confer health benefits, including longevity and disease prevention. Although CR is promising in preventing chronic kidney disease (CKD), its potential impact on the progression of kidney fibrosis from acute kidney injury (AKI) to CKD remains unclear. Here, we present evidence that CR exacerbates renal damage in a mouse model of folic acid (FA)-induced renal fibrosis by altering mitochondrial metabolism and inflammation. Mice subjected to CR (60% of ad libitum) for three days were subjected to high dose of FA (250 mg/kg) injection and maintained under CR for an additional week before being sacrificed. Biochemical analyses showed that CR mice exhibited increased kidney injury and fibrosis. RNA sequencing analysis demonstrated decreased electron transport and oxidative phosphorylation (OXPHOS) in CR kidneys with injury, heightened inflammatory, and fibrotic responses. CR significantly decreased OXPHOS gene and protein levels and reduced β-oxidation-associated proteins in the kidney. To determine whether defects in mitochondrial metabolism is associated with inflammation in the kidney, further in vitro experiments were performed. NRK52E kidney epithelial cells were treated with antimycin A to induce mitochondrial damage. Antimycin A treatment significantly increased chemokine expression via a STING-dependent pathway. Serum restriction in NRK49F kidney fibroblasts was observed to enhance the fibrotic response induced by TGFβ under in vitro conditions. In summary, our results indicate that CR exacerbates fibrosis and inflammatory responses in the kidney by altering mitochondrial metabolism, highlighting the importance of adequate energy supply for an effective response to AKI and fibrosis development.
All participants enrolled in the olfactory enrichment group will receive twice sessions per day with an interval of at least 6 hours on preoperative day 1-3 and postoperative day 1-3 (or postoperative day 1-discharge day). Each session will last 30 minutes. Each participant will be equipped with an electrical odor dispenser which allowed to distribute 8 odors (grapefruit, lavender, lemon, peppermint, tangerine, green tea, cloves and eucalyptus). When pushing a button, 4 odors will be released in turn and participants will sniff each odor (approximately 4 ml odorized air) for approximately 30 seconds by a nasal catheter. Considering of the adaption of odors, 4 odors will be used in the morning session and another 4 odors will be used in the afternoon session.
The 15 attentional control group stroke survivors will receive phone calls over the 12-week intervention checking in with them on how they are doing in their everyday life. They will also receive stroke education materials, but they will not receive the same iSMART intervention as the intervention group.
Initially all participants receive Fampridine-SR 10 mg BID in an open label enrichment phase lasting four weeks. Those 40% responding the most by SSST will go onto phase two. 50% of these will receive 10 mg Fampridine-SR BID for four weeks.
Procedures involved in this study include:

- Intraoperatively, following procurement of the fibula or scapula bone graft and at the time of surgical wound closure, all patients will receive the placement of a continuous infusion catheter into the donor site wound bed. The infusion reservoir will be connected to a catheter-based On-Q pump, and the catheter will be placed in the donor site. A stab incision separate from the surgical wound will be used to bring the catheter through the skin. Patients will be randomized to receive 6 ml/hr of 0.2% Ropivacaine or 6 ml/hr of normal saline via the infusion reservoir. The catheter will be left in place with continuous infusion for first 48 hours of the post-operative period. The catheters will be removed by the housestaff on POD2. There is minimal risk to removing the OnQ catheter. Any opening in the skin will be covered with gauze to allow primary healing. Solutions of saline and ropivacaine will be prepared and made available for infusion by the Mount Sinai Pharmacy. Solutions will be blinded, and identical in appearance. Patients will be assigned to ropivacaine or saline intervention by the research pharmacy through coded envelopes. Patients, physicians, nurses, and research personnel will be blinded to treatment assignment. Every 8 hours for the first 48 hours, patients will be asked to complete a visual analogue scale (VAS) for reporting their pain. The VAS will be performed six times over the course of the 48hrs. These will be performed during regular flap check monitoring, to ensure patients are not disrupted additional times throughout the day for this study. Patients will otherwise receive standard of care pain management, including Tylenol 650 q6hr standing as well as a dilaudid PCA set to low-dose, opioid naïve. On post-operative day 2 patient will receive a physical therapy evaluation.

Prior to discharge from the hospital, the study subjects will be asked to complete a brief survey (APS-POQ-R Pain Survey) regarding their experience, with regard to pain management.
Notably, pediatric regimens for adult acute lymphoblastic leukemia (ALL) have resulted in better long-term outcomes, especially in the Philadelphia-negative counterpart. These regimens are essentially based on higher cumulative doses of asparaginase and the use of less myelotoxic agents, applying allogeneic transplantation only for high-risk ALL subsets. Recent metanalysis encompassing 27 clinical trials demonstrated an improved prognosis when these regimens are adopted. In adults, incorporation of these regimens has been hampered by a perception of higher toxicity and a more complex design, especially with asparaginase. Remarkably, this drug might bring side effects not usually seen with other cancer drugs, such as thrombosis, liver, and pancreatic toxicities. In addition, the incorporation of minimal residual disease (MRD) monitoring throughout the treatment protocol in a scheduled and standardized manner is considered paramount in the contemporary ALL treatment. Treating adult patients with acute leukemia under prospective studies allows accurate data collection and positively impacts the disease prognosis, creating a cooperative scientific environment. In Brazil, few data are available on the clinical- laboratory characteristics of ALL in adults and their outcomes under a standardized treatment protocol. Few single-center reports point to a worse overall survival rate when compared to developed countries. There is great heterogeneity across the centers regarding the treatment regimens and genetic/MRD assessment. In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic/follow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. At the diagnosis, a genetic characterization encompassing conventional karyotype, fluorescent in-situ hybridization (FISH), and molecular biology in our central laboratory will be performed to classify the cases. Genomic classification will include identifying Philadelphia- like B-cell ALL cases, a recent group of cases with worse prognosis, whose incidence seems higher in Hispanics. In Brazil, there is no study addressing this incidence and, more importantly, evaluating its impact on outcomes under a standardized treatment protocol. MRD analysis will also be centralized to standardize and validate our flow cytometry panel in a homogeneous cohort. Additionally, the investigators plan to assess baseline factors predictive of survival and relapse and those related to major toxicities such as infections, liver toxicity, and thrombosis.
PURPOSE:To obtain a medicine for prevention and therapy of osteoporosis, containing minerals and an indigestible oligosaccharide, excellent in absorption of calcium and capable of preventing reduction of the amount of bone-salt or reduction of bone density observed in osteoporosis. CONSTITUTION:This medicine contains minerals (at least calcium among calcium, magnesium, phosphorus and iron) and an indigestible oligosaccharide (e.g. fructo-oligosaccharide). The ratio of calcium in the minerals to the indigestible oligo-saccharide is 1:1 to 1:20, preferably 1:5 to 1:10 on weight base. As the dosage form, any type of granule, capsule, tablet, powder, liquid, etc., may be used. This medicine also can be taken as a food in the form of a mixture prepared by adding another food, seasonings, food additives, etc.,or in the form of simple component not containing them. If the indigestible oligo-saccharide is contained so as to be intaken in an amount of about 10g per day, this medicine has a favorable control effect on intestinal functions. This medicine can effectively prevent especially osteoporosis frequently observed in postmenoposal women or retard the advancement of it.
A system links data objects for common entities across source systems and includes at least one processor. The system compares data objects within each of a plurality of source systems to identify data objects associated with corresponding common entities. The identified data objects for each common entity within each of the plurality of source systems are linked to form a group of data objects for each common entity. The groups of data objects for each of the common entities are compared across the plurality of source systems to identify groups of data objects associated with common entities. The identified groups of data objects for common entities are linked across the plurality of source systems to form a set of data objects for each corresponding common entity. Embodiments of the present invention further include a method and computer program product for linking data objects for common entities across source systems.
A pharmaceutical composition contains a one-layer tablet core having a polymeric film-coat, therapeutically active agent and hydrophilic polymer. It further contains, if desired, a two-layer tablet core comprising an active agent and hydrophilic polymer in the first layer of this core and a hydrophilic polymer in the second layer of this core. The tablet core further has at least one bore on the film-coat being in contact with the tablet core or the layer thereof containing the active agent, and, if desired, it contains one or more bores that are in contact with the second layer having a hydrofylic polymer, which contains ammonium methacrylate copolymer as the coating material and hydroxypropyl-methylcellulose as the hydrophilic polymer. The composition is suitable for the preparation of tablets with a controlled drug-release and containing active agents, e.g. beta-adrenergic inhibitors (e.g. propanolol), calcium antagonists (e.g. nifedipin), ACE (angiotensin-converting enzyme) inhibitors, (e.g. captopril), prazosin or nitroglycerine, all of them used in the treatment of cardio-circular diseases; vasodilatatory agents (e.g pentoxifylline); nonsteroidal anti-inflammatory agents (e.g. naproxene); analgesics (e.g. morphine); and CNS agents (e.g. amitriptyline, buspirone). There is further disclosed a method for the preparation of said compositions.
FIELD: hygiene.SUBSTANCE: group of inventions relates to oral care. Anhydrous dentifrice composition contains a bleaching complex containing cross-linked polyvinylpyrrolidone in complex with hydrogen peroxide, wherein complex is present in amount of 10 to 15 wt. % in terms of total weight of composition; reducing release of gas agent, which is sodium sulphate, present in amount of 0.02 wt. % to 0.15 wt. % in terms of total weight of composition; and additional linear and/or cross-linked polyvinylpyrrolidone; abrasive present in amount of 0.1 wt. % to 40 wt. % in terms of total weight of composition; and carrier acceptable for application in oral cavity. Also disclosed is a method for preparing an anhydrous dentifrice composition and another version of an anhydrous dentifrice composition.EFFECT: group of inventions provides reduced release of gas from the dentifrice.12 cl, 1 tbl, 1 ex
High perioperative mortality and complication rates during the coronavirus disease 2019 (COVID-19) pandemic have been reported. In head and neck reconstruction, not only is patient safety important, but the prevention of infection introduced by the surgical team is also important because the procedure is performed in close proximity to the upper respiratory tract. In addition, recent studies have reported an increased risk for thrombus formation after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 vaccination, which is problematic for microsurgical reconstruction procedures. At the authors' institution, patients undergoing head and neck reconstruction are requested to stay home for 2 weeks and undergo screening tests for COVID-19 before admission. Surgeons use standard personal protective equipment during surgery. There was no significant difference in the rate of total flap necrosis between the COVID-19 and non-pandemic periods or large difference of perioperative complication rates between vaccinated and non-vaccinated patients. No surgery-related infections among the surgical staff were also found.